力生制药：药品氯化钾缓释片通过上市许可申请

Core Viewpoint - The company has received drug registration certificates for two specifications of potassium chloride sustained-release tablets, indicating successful approval for market entry [1] Group 1 - The company announced the receipt of the drug registration certificate for potassium chloride sustained-release tablets in 0.5g specification [1] - The company also received the drug registration certificate for potassium chloride sustained-release tablets in 0.6g specification [1] - Both products have successfully passed the drug market licensing application [1]